Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 92Lung Neoplasms 32NSCLC 7Brain Neoplasms 7Meningeal Carcinomatosis 4Neoplasm Metastasis 3Carcinoma, Squamous Cell 2Bronchial Neoplasms 2Adenocarcinoma of Lung 2Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Prostatic Neoplasms 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Carcinoma 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non-Small Cell Lung Cancer With EGFR T790M Mutation 1Non-Small Cell Lung Cancer With EGFR Mutation 1Non Small Cell Lung Cancer Metastatic 1Neurocognitive 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lung Cancer Metastatic 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Glioblastoma 1Eunuchism 1Erectile Dysfunction 1

Interventions

regramostim 1osimertinib 1evolocumab 1Surgical Instruments 1Radiotherapy 1Radiation 1Nivolumab 1Needles 1MLN 8237 1Ipilimumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Cancer Metastatic × osimertinib × Clear all
NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1 Recruiting
38 enrolled
Thoracic

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡